JP7682605B2 - 過活動膀胱を治療するためのビベグロンの使用 - Google Patents

過活動膀胱を治療するためのビベグロンの使用 Download PDF

Info

Publication number
JP7682605B2
JP7682605B2 JP2019567995A JP2019567995A JP7682605B2 JP 7682605 B2 JP7682605 B2 JP 7682605B2 JP 2019567995 A JP2019567995 A JP 2019567995A JP 2019567995 A JP2019567995 A JP 2019567995A JP 7682605 B2 JP7682605 B2 JP 7682605B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
vibegron
composition
human
over
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019567995A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020522560A5 (https=
JP2020522560A (ja
Inventor
シー．ピシテッリ ステファン
マッド ポール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Urovant Sciences GmbH
Original Assignee
Urovant Sciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62815097&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7682605(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Urovant Sciences GmbH filed Critical Urovant Sciences GmbH
Publication of JP2020522560A publication Critical patent/JP2020522560A/ja
Publication of JP2020522560A5 publication Critical patent/JP2020522560A5/ja
Priority to JP2023030625A priority Critical patent/JP2023071826A/ja
Priority to JP2025005498A priority patent/JP2025063196A/ja
Application granted granted Critical
Publication of JP7682605B2 publication Critical patent/JP7682605B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2019567995A 2017-06-06 2018-06-06 過活動膀胱を治療するためのビベグロンの使用 Active JP7682605B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023030625A JP2023071826A (ja) 2017-06-06 2023-03-01 過活動膀胱を治療するためのビベグロンの使用
JP2025005498A JP2025063196A (ja) 2017-06-06 2025-01-15 過活動膀胱を治療するためのビベグロンの使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762515996P 2017-06-06 2017-06-06
US62/515,996 2017-06-06
US201862635146P 2018-02-26 2018-02-26
US62/635,146 2018-02-26
US201862637961P 2018-03-02 2018-03-02
US62/637,961 2018-03-02
PCT/IB2018/054069 WO2018224989A1 (en) 2017-06-06 2018-06-06 Use of vibegron to treat overactive bladder

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2023030625A Division JP2023071826A (ja) 2017-06-06 2023-03-01 過活動膀胱を治療するためのビベグロンの使用
JP2025005498A Division JP2025063196A (ja) 2017-06-06 2025-01-15 過活動膀胱を治療するためのビベグロンの使用

Publications (3)

Publication Number Publication Date
JP2020522560A JP2020522560A (ja) 2020-07-30
JP2020522560A5 JP2020522560A5 (https=) 2021-07-26
JP7682605B2 true JP7682605B2 (ja) 2025-05-26

Family

ID=62815097

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019567995A Active JP7682605B2 (ja) 2017-06-06 2018-06-06 過活動膀胱を治療するためのビベグロンの使用
JP2023030625A Pending JP2023071826A (ja) 2017-06-06 2023-03-01 過活動膀胱を治療するためのビベグロンの使用
JP2025005498A Pending JP2025063196A (ja) 2017-06-06 2025-01-15 過活動膀胱を治療するためのビベグロンの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023030625A Pending JP2023071826A (ja) 2017-06-06 2023-03-01 過活動膀胱を治療するためのビベグロンの使用
JP2025005498A Pending JP2025063196A (ja) 2017-06-06 2025-01-15 過活動膀胱を治療するためのビベグロンの使用

Country Status (14)

Country Link
US (2) US12102638B2 (https=)
EP (2) EP3634420A1 (https=)
JP (3) JP7682605B2 (https=)
KR (2) KR20200012949A (https=)
CN (3) CN117695286A (https=)
AU (2) AU2018282104B2 (https=)
BR (1) BR112019025636A2 (https=)
CA (1) CA3064989A1 (https=)
CL (1) CL2019003533A1 (https=)
IL (2) IL317220A (https=)
MX (1) MX2022015629A (https=)
PH (1) PH12019502651A1 (https=)
WO (1) WO2018224989A1 (https=)
ZA (1) ZA202000028B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102735800B1 (ko) * 2017-12-21 2024-11-28 교린 세이야쿠 가부시키가이샤 야간빈뇨 치료제
SG11202103662VA (en) * 2018-12-05 2021-06-29 Urovant Sciences Gmbh Vibegron for the treatment of overactive bladder symptoms
JP2022524576A (ja) * 2019-03-18 2022-05-09 ウロバント サイエンシズ ゲーエムベーハー 過活動膀胱を処置するためのビベグロンの使用
DE102020124101A1 (de) 2020-02-04 2021-08-05 Samsung Electronics Co., Ltd. Elektronische vorrichtung mit einer speichervorrichtung und trainingsverfahren
CA3202926A1 (en) * 2020-12-22 2022-06-30 Paul N. Mudd Jr. Methods of monitoring digoxin with concomitant use of vibegron to treat overactive bladder
WO2025262600A1 (en) 2024-06-17 2025-12-26 Urovant Sciences Gmbh Crystalline form of vibegron hemihydrate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016503001A (ja) 2012-12-14 2016-02-01 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ Ｇａｂａａ受容体モジュレーターとしてのイミダゾピリダジン誘導体

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE266639T1 (de) 1997-10-17 2004-05-15 Yamanouchi Pharma Co Ltd Amidderivate oder deren salze
GB9812709D0 (en) 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
US6562375B1 (en) 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
GB0015246D0 (en) * 2000-06-22 2000-08-16 Astrazeneca Ab Method for the treatment of urinary incontinence
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US7342117B2 (en) 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
DOP2003000587A (es) 2002-02-27 2003-08-30 Pfizer Prod Inc AGONISTAS DEL RECEPTOR ß3-ADRENERGICO
DK1559427T3 (da) 2002-11-07 2011-04-26 Astellas Pharma Inc Lægemiddel til overaktiv blære omfattende eddikesyreanilidderivat som den aktive bestanddel
DK1620085T3 (da) 2003-05-05 2008-11-24 Kissei Pharmaceutical Anvendelse af phenoxyacetatsyrederivater til behandling af hyperaktiv blære
FR2874011B1 (fr) 2004-08-03 2007-06-15 Sanofi Synthelabo Derives de sulfonamides, leur preparation et leur application en therapeutique
CA2682676A1 (en) 2007-04-19 2008-10-30 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptor-5
EP2198018B1 (en) 2007-09-13 2013-11-20 Codexis, Inc. Ketoreductase polypeptides for the reduction of acetophenones
CA2704298C (en) 2007-11-02 2015-07-21 Astellas Pharma Inc. Pharmaceutical composition for treating overactive bladder
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
US8273554B2 (en) 2008-08-29 2012-09-25 Codexis, Inc. Ketoreductase polypeptides for the stereoselective production of (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one
WO2011043942A1 (en) 2009-10-07 2011-04-14 Merck Sharp & Dohme Corp. Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent
WO2011137054A1 (en) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
AU2011285928B9 (en) 2010-08-03 2018-08-02 B3Ar Therapeutics, Inc. Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
AU2012323890A1 (en) 2011-10-14 2014-05-29 Array Biopharma Inc. Polymorphs of arry-380, a selective ErbB2 inhibitor and pharmaceutical compositions containing them
ES2584427T3 (es) 2011-10-27 2016-09-27 Merck Sharp & Dohme Corp. Proceso para la preparación de agonistas beta 3 y productos intermedios
WO2013062881A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
IN2014CN04470A (https=) 2011-11-18 2015-09-04 Codexis Inc
EP2606894A1 (en) 2011-12-20 2013-06-26 Sanofi Novel therapeutic use of p75 receptor antagonists
RS59402B1 (sr) 2013-03-15 2019-11-29 Merck Sharp & Dohme Postupak za pripremu beta 3 agonista i međuproizvoda
HK1245117A1 (zh) 2014-12-03 2018-08-24 Velicept Therapeutics, Inc. 使用调节释放索拉贝隆用於下尿路症状的组合物和方法
ES2967863T3 (es) 2015-10-23 2024-05-06 B3Ar Therapeutics Inc Ion dipolar de solabegron y usos del mismo
US20170348288A1 (en) 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder
EP3463307A4 (en) 2016-06-03 2020-01-15 Velicept Therapeutics, Inc. COMPOSITIONS AND METHODS FOR USE OF SOLABEGRON WITH MODIFIED RELEASE FOR SYMPTOMS OF THE LOWER URINARY PATHWAYS
JP7670461B2 (ja) 2017-06-06 2025-04-30 ウロバント サイエンシズ ゲゼルシャフト ミット ベシュレンクター ハフトゥング 過活動膀胱の治療のためのビベグロンの投薬
KR102735800B1 (ko) 2017-12-21 2024-11-28 교린 세이야쿠 가부시키가이샤 야간빈뇨 치료제
SG11202010683PA (en) 2018-05-23 2020-12-30 Urovant Sciences Gmbh Use of vibegron to treat pain associated with irritable bowel syndrome
SG11202103662VA (en) 2018-12-05 2021-06-29 Urovant Sciences Gmbh Vibegron for the treatment of overactive bladder symptoms
JP2022524576A (ja) 2019-03-18 2022-05-09 ウロバント サイエンシズ ゲーエムベーハー 過活動膀胱を処置するためのビベグロンの使用
CA3202926A1 (en) 2020-12-22 2022-06-30 Paul N. Mudd Jr. Methods of monitoring digoxin with concomitant use of vibegron to treat overactive bladder
TW202245781A (zh) 2021-02-16 2022-12-01 瑞士商優洛凡特科學公司 用維貝格龍（ｖｉｂｅｇｒｏｎ）治療心臟衰竭之方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016503001A (ja) 2012-12-14 2016-02-01 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ Ｇａｂａａ受容体モジュレーターとしてのイミダゾピリダジン誘導体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OA, Clinicaltrials.gov, 2016年06月17日, 発行日, Study Results
DI SALVO, J., et al., Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antim, Journal of Pharmacology and Experimental Therapeutics, 2017年02月01日, 発行日, Vol.360, No.2, pp.346-355
EDMONDSON, S.D., et al., Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of O, Journal of Medicinal Chemistry, 2016, 発行日, Vol.59, No.2, pp.609-623

Also Published As

Publication number Publication date
US20210077495A1 (en) 2021-03-18
IL271164A (en) 2020-01-30
CN110869022A (zh) 2020-03-06
MX2022015629A (es) 2023-01-11
US20260014158A1 (en) 2026-01-15
JP2025063196A (ja) 2025-04-15
JP2020522560A (ja) 2020-07-30
ZA202000028B (en) 2025-09-25
WO2018224989A1 (en) 2018-12-13
JP2023071826A (ja) 2023-05-23
CL2019003533A1 (es) 2020-06-26
AU2018282104B2 (en) 2024-07-11
KR20250099259A (ko) 2025-07-01
EP4410295A3 (en) 2024-10-16
AU2024204591A1 (en) 2024-07-18
IL317220A (en) 2025-01-01
US12102638B2 (en) 2024-10-01
EP4410295A2 (en) 2024-08-07
CA3064989A1 (en) 2018-12-13
AU2018282104A1 (en) 2019-12-12
CN117695287A (zh) 2024-03-15
PH12019502651A1 (en) 2020-06-08
CN117695286A (zh) 2024-03-15
BR112019025636A2 (pt) 2020-08-25
EP3634420A1 (en) 2020-04-15
KR20200012949A (ko) 2020-02-05

Similar Documents

Publication Publication Date Title
JP7682605B2 (ja) 過活動膀胱を治療するためのビベグロンの使用
JP7670461B2 (ja) 過活動膀胱の治療のためのビベグロンの投薬
JP2025032143A (ja) 良性前立腺肥大症の男性の過活動膀胱症状を治療するためのビベグロンの使用
US20210196720A1 (en) Use of vibegron to treat pain associated with irritable bowel syndrome
HK40114255A (en) Use of vibegron to treat overactive bladder
EA045454B1 (ru) Применение вибегрона для лечения гиперактивного мочевого пузыря
HK40126413A (en) Use of vibegron to treat overactive bladder symptoms in men with benign prostatic hyperplasia
EA052961B1 (ru) Вибегрон для лечения симптомов гиперактивного мочевого пузыря

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210514

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210514

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220628

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230301

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230301

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230421

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230424

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230425

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250115

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250514

R150 Certificate of patent or registration of utility model

Ref document number: 7682605

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150